当前位置:首页 - 行情中心 - 泽璟制药-U(688266) - 财务分析 - 现金流量表

泽璟制药-U

(688266)

  

流通市值:284.01亿  总市值:284.01亿
流通股本:2.65亿   总股本:2.65亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,265,861,458.68942,973,341.74893,841,042.09625,943,869.14
  收到其他与经营活动有关的现金225,668,877.49201,757,747.59161,640,556.03140,197,696.51
  经营活动现金流入小计1,491,530,336.171,144,731,089.331,055,481,598.12766,141,565.65
  购买商品、接受劳务支付的现金31,477,314.0411,601,930.2942,077,111.9824,889,535.54
  支付给职工以及为职工支付的现金209,890,271.94117,092,176.67343,267,920.11256,185,507.54
  支付的各项税费43,115,278.4517,789,141.9780,563,439.9851,276,975.12
  支付其他与经营活动有关的现金398,533,558.62160,833,344.28618,355,112.29450,523,469.31
  经营活动现金流出小计683,016,423.05307,316,593.211,084,263,584.36782,875,487.51
  经营活动产生的现金流量净额808,513,913.12837,414,496.12-28,781,986.24-16,733,921.86
二、投资活动产生的现金流量:
  收回投资收到的现金1,901,152,926.26396,585,777.77116,123,50065,492,200
  取得投资收益收到的现金115,156,212.6531,652,958.349,708,791.34451,333.33
  投资活动现金流入小计2,016,309,138.91428,238,736.11125,832,291.3465,943,533.33
  购建固定资产、无形资产和其他长期资产支付的现金49,416,816.333,799,619.54181,466,703.44132,497,229.06
  投资支付的现金1,554,454,330.32999,454,330.32--
  投资活动现金流出小计1,603,871,146.621,033,253,949.86181,466,703.44132,497,229.06
  投资活动产生的现金流量净额412,437,992.29-605,015,213.75-55,634,412.1-66,553,695.73
三、筹资活动产生的现金流量:
  取得借款收到的现金56,000,00056,000,0001,126,882,468.69616,021,145.08
  筹资活动现金流入小计56,000,00056,000,0001,126,882,468.69616,021,145.08
  偿还债务支付的现金370,200,000.03201,900,0001,009,900,000.01507,070,075.83
  分配股利、利润或偿付利息支付的现金10,942,041.825,794,834.326,094,317.7919,466,662.08
  支付其他与筹资活动有关的现金12,487,913.846,286,829.4498,389,163.0690,169,404.09
  筹资活动现金流出小计393,629,955.69213,981,663.741,134,383,480.86616,706,142
  筹资活动产生的现金流量净额-337,629,955.69-157,981,663.74-7,501,012.17-684,996.92
四、汇率变动对现金及现金等价物的影响-5,348,578.27-4,503,785.11-690,409.18-527,602.39
五、现金及现金等价物净增加额877,973,371.4569,913,833.52-92,607,819.69-84,500,216.9
  加:期初现金及现金等价物余额124,657,673.39124,657,673.39217,265,493.08217,265,493.08
  期末现金及现金等价物余额1,002,631,044.84194,571,506.91124,657,673.39132,765,276.18
补充资料:
  净利润640,011,104.13--165,126,809.51-
  资产减值准备5,320,810.83-3,358,105.87-
  固定资产和投资性房地产折旧10,407,581.7-23,670,592.77-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧10,407,581.7-23,670,592.77-
  无形资产摊销5,958,398.69-18,628,973.79-
  长期待摊费用摊销2,100,944.51-5,628,883.62-
  处置固定资产、无形资产和其他长期资产的损失19,991.64--810.44-
  固定资产报废损失1,999.23---
  公允价值变动损失-1,553,465.55--841,343.86-
  财务费用3,471,836.86--29,626,727.88-
  投资损失-1,002,696.24--358,908.26-
  递延所得税-1,610,428.25--3,996,929.58-
    递延所得税负债增加-1,610,428.25--3,996,929.58-
  存货的减少-24,926,294.72-9,594,088.46-
  经营性应收项目的减少-62,042,396.89--24,395,644.32-
  经营性应付项目的增加225,637,556.92-123,550,059.88-
  其他--3,339,332.01-
  不涉及现金收支的投资和筹资活动金额其他项目--0-
  现金的期末余额1,002,631,044.84-124,657,673.39-
  减:现金的期初余额124,657,673.39-217,265,493.08-
  现金及现金等价物的净增加额877,973,371.45--92,607,819.69-
公告日期2026-08-012026-04-292026-03-282025-10-31
审计意见(境内)标准无保留意见
TOP↑